MAP's drug, Levadex, showed statistical significance at two hours compared to placebo at relieving common symptoms of migraine: pain, nausea, and sensitivity to light and sound.
Levadex, formerly called MAP0004, also reached secondary measures of the 792-patient trial, including pain relief at 30 minutes and sustained relief for 48 hours.
Read moreMAP Pharmaceuticals recently completed patient enrollment in the efficacy (effectiveness) part of its initial Phase 3 clinical trial... Read more »
"The National Institutes of Health Blueprint for Neuroscience Research is launching a $30 million project that will use cutting-edge brain... Read more »
As Migrainuers, we're always looking for better abortive medications to stop Migraines and their associated symptoms in their tracks. The... Read more »
When we discuss with others what we’re learning, we retain that new knowledge much better than when we just passively engage with the new... Read more »
Recent research to emerge from the Indiana University School of Medicine suggests that hundreds of genes are involved in bipolar disorder.... Read more »
As MigrainuersAs Migrainuers, we're always looking for better abortive medications to stop Migraines and their associated symptoms in their tracks.... Read more »
Indiana University researchers say they have created the first comprehensive map of the genes involved in bipolar disorder. According to a university... Read more »
A San Diego company is reporting that it has decoded the complete genome map of actress Glenn Close, a long-time advocate for people with mental... Read more »
To decide which health insurance plan is best for you, you need to determine how much you will be spending on medical care in the future. There are... Read more »
To decide which health insurance plan is best for you, you need to determine how much you will be spending on medical care in the future. There are... Read more »